Cargando…

Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome s...

Descripción completa

Detalles Bibliográficos
Autor principal: Nakajima, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523542/
https://www.ncbi.nlm.nih.gov/pubmed/23304532
http://dx.doi.org/10.1155/2012/950693
_version_ 1782253225296003072
author Nakajima, Kei
author_facet Nakajima, Kei
author_sort Nakajima, Kei
collection PubMed
description Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver disorders. In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well as clinical parameters. Accordingly, insulin sensitizers, antioxidative agents, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, RAS blockers, and drugs that target the central nervous system may represent candidate pharmacotherapies for NAFLD and possibly NASH. However, the efficacy, safety, and tolerability of long-term treatment (potentially for many years) with these drugs have not been fully established. Furthermore, clinical trials have not comprehensively examined the efficacy of lipid-lowering drugs (i.e., statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. Although clinical evidence for RAS blockers and incretin-based agents (GLP-1 analogs and dipeptidyl peptidase-4 inhibitors) is also lacking, these agents are promising in terms of their insulin-sensitizing and anti-inflammatory effects without causing weight gain.
format Online
Article
Text
id pubmed-3523542
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35235422013-01-09 Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease Nakajima, Kei Int J Hepatol Review Article Nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are multidisciplinary liver diseases that often accompany type 2 diabetes or metabolic syndrome, which are characterized by insulin resistance. Therefore, effective treatment of type 2 diabetes and metabolic syndrome should target not only the cardiometabolic abnormalities, but also the associated liver disorders. In the last decade, it has been shown that metformin, thiazolidinediones, vitamin E, ezetimibe, n-3 polyunsaturated fatty acids, renin-angiotensin system (RAS) blockers, and antiobesity drugs may improve hepatic pathophysiological disorders as well as clinical parameters. Accordingly, insulin sensitizers, antioxidative agents, Niemann-Pick C1-like 1 (NPC1L1) inhibitors, RAS blockers, and drugs that target the central nervous system may represent candidate pharmacotherapies for NAFLD and possibly NASH. However, the efficacy, safety, and tolerability of long-term treatment (potentially for many years) with these drugs have not been fully established. Furthermore, clinical trials have not comprehensively examined the efficacy of lipid-lowering drugs (i.e., statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. Although clinical evidence for RAS blockers and incretin-based agents (GLP-1 analogs and dipeptidyl peptidase-4 inhibitors) is also lacking, these agents are promising in terms of their insulin-sensitizing and anti-inflammatory effects without causing weight gain. Hindawi Publishing Corporation 2012 2012-12-09 /pmc/articles/PMC3523542/ /pubmed/23304532 http://dx.doi.org/10.1155/2012/950693 Text en Copyright © 2012 Kei Nakajima. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Nakajima, Kei
Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
title Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
title_full Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
title_fullStr Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
title_full_unstemmed Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
title_short Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
title_sort multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523542/
https://www.ncbi.nlm.nih.gov/pubmed/23304532
http://dx.doi.org/10.1155/2012/950693
work_keys_str_mv AT nakajimakei multidisciplinarypharmacotherapeuticoptionsfornonalcoholicfattyliverdisease